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 ABSTRACT  
BACKGROUND: In resource-rich countries, chronic hepatitis C (CHC) infection is 
associated with a sizeable excess mortality risk. The extent to which this is due to: (a) the 
biological sequelae of CHC infection, versus b) a high concomitant burden of health risk 
behaviours (HRBs), is unclear.  
METHODS: We used data from the 1999-2010 US National-Health-and-Nutritional-
Examination-Surveys (NHANES), which include detailed information on HRBs and CHC 
infection status. We calculated the prevalence of the five major HRBs – alcohol use; cigarette 
smoking, physical inactivity, unhealthy diet, and illicit drug use –according to CHC after 
adjusting for socio-demographic differences. Mortality status after survey interview was 
ascertained via linkage to the US National Death Index. To assess the contribution of HRBs 
to the excess mortality risk, we determined the all-cause mortality rate ratio (MRR) for 
individuals with CHC relative to individuals without, and then calculated the attenuation in 
this MRR following adjustment for HRBs.  
RESULTS: This analysis included 27,468 adult participants of NHANES of which 363 tested 
positive for CHC. All HRBs were markedly more prevalent among individuals with CHC 
versus individuals without. CHC was associated with a 2.4-fold higher mortality rate after 
adjustment for socio-demographic factors (MRR:2.36;95%CI:1.60-3.49). Subsequent 
adjustment for all five HRBs attenuated this ratio by 50.7% to MRR:1.67(95%CI:1.14-2.44). 
Higher levels of attenuation (69.1%) were observed among individuals aged 45-70yrs, who 
form the target demographic for US birth cohort screening.  
CONCLUSION: At least half the excess mortality risk for individuals with CHC in the US 
may be due to HRBs rather than CHC. The remedial response to hepatitis C must not neglect 







Chronic hepatitis C (CHC) infection is a major global health concern, affecting 
approximately 80 million people worldwide.[1]  CHC is associated with considerable excess 
mortality in resource-rich settings. In Western Europe, North America and Australia, all-
cause mortality rates are 3.1-6.7 times higher among individuals diagnosed with HCV 
antibodies versus the general population (after adjustment for age, sex and calendar year) [2-
7]. The elevated mortality risk is most pronounced in younger age groups. For example, all-
cause mortality is 9.0 times higher than the general population among infected persons in 
Scotland aged 20-49 years, but only 3.7 times higher among infected persons aged ≥50 years. 
[3] 
Understanding the factor(s) driving this excess mortality risk is a pre-requisite to an effective 
remedial response. Currently, the extent to which the excess mortality reflects: (a) the 
biological sequelae of CHC infection, versus b) a high concomitant burden of health risk 
behaviours (HRBs), is unclear. On the one hand, CHC infection causes persistent 
inflammation and scarring of the liver, which over time can lead to liver cirrhosis and liver 
cancer. [8] CHC infection has also been causally linked to a wide variety of extrahepatic 
diseases including diabetes, non-hodgkins lymphoma and cardiovascular disease. [9-11] On 
the other hand, data are emerging that suggest HRBs play an important contributory role to 
the impaired survival of this population. Approximately a third of CHC patients attending 
liver clinics self-report a history of heavy alcohol, whilst more than half report previous 
injecting drug use. [12. 13] Studies examining what people diagnosed with hepatitis C die 
from in resource-rich settings indicate two dominant causes of death.[14] Firstly, drug-related 
mortality (accounting for 18-27% of total deaths);and secondly, liver disease (accounting for 
18-24% of total mortality). Of mortality due to liver disease, we previously estimated that 
only 55-66% is attributable to CHC in Denmark and Scotland.[15], and speculated that the 
residual component may reflect the consequences of excess alcohol use (which is strongly 
associated with liver cirrhosis and liver mortality in persons with CHC. [16,17,13]). Further, 
although cure of CHC is associated with a reduction in mortality risk,[18,19] mortality 
nevertheless remains 1.9 times higher than the general population in cured patients, with 
health behaviours (specifically markers of heavy alcohol use and injecting drug use) being 
key mortality determinants. [20]  
Thus far, no study has systematically examined the collective contribution of the five major 
 HRBs - excess alcohol use, cigarette smoking, physical inactivity, unhealthy diet, and illicit 
drug use [21] - to the excess mortality risk in persons with CHC. And particularly no study 
has done so in a sample representative of the CHC-infected population as a whole (i.e. most 
studies are confined to diagnosed individuals, thereby ignoring the appreciable proportion, 
typically >50% [32], of the infected population that are unaware of their infection). 
Therefore, in this study, we analysed general-population data from the US continuous 
National Health and Nutritional Examination Survey (NHANES) which is unique in 
including individual-level data on: 1) baseline chronic HCV status; 2) self-reported HRBs; 
and 3) subsequent mortality events through to Dec 2011. Specific questions that we set out to 
address in this study were as follows. Firstly, what is the size of the excess mortality risk in a 
population-based sample (i.e. inclusive of diagnosed and undiagnosed persons), after 
adjusting for basic socio-demographic factors? Secondly, what are the prevalence differences 
in the five major HRBs according to CHC infection status? Thirdly, to what extent do any 
















BRIEF DESCRIPTION OF NHANES 
The continuous National Health and Nutritional Examination Survey (NHANES) is a large 
cross-sectional health survey of the US population. The survey was first carried out in the 
year 1999 and has been repeated annually ever since. The survey sample - comprising c.5000 
individuals per year - is selected through a complex multistage process that ensures 
generalizability to the US civilian non-institutionalised household population (see [23] for 
more details). Participation in NHANES entails completion of an initial household interview 
and/or a detailed health examination conducted in a bespoke mobile examination centre 
(MEC). Data collected on survey participants include, inter alia, information pertaining to: 
socio-economic factors; demographic factors; medical history; HRBs; and 
medical/physiological measurements. In addition, various laboratory tests- including tests for 
CHC and other blood borne viruses - are carried out on participant urine and blood 
specimens. [24] Although NHANES includes representation from all age groups, data on 
alcohol, drug and tobacco-related HRBs are only publicly available for participants aged ≥20 
years. The raw data used in this analysis can be found at: 
https://wwwn.cdc.gov/nchs/nhanes/Default.aspx  
INCLUSION CRITERIA:  
We included all adults (defined as age ≥20 years at time of survey interview) who 
participated in NHANES from 1999 to 2010; and who completed the household interview, 
MEC examination and dietary questionnaire components of the survey. We excluded any 
individuals with unknown CHC infection status and/or any individual who could not be 
linked to the national death index. NHANES participants from years 2011 onwards were not 
included in this analysis because their post-survey mortality data were not available in the 
latest public use linked mortality file.  
MAJOR DATA VARIABLES 
We characterised survey participants with respect to: 1.socio-demographic factors, 2.current 
HRBs (i.e. HRBs present at the time of the survey interview); 3.former HRBs (HRBs present 
in the past but not at the time of survey interview); 4. CHC infection status; 5. comorbid 
medical conditions; and 6. mortality status through to 31 Dec 2011.   
 1.0: DATA ON SOCIO-DEMOGRAPHIC FACTORS: 
Socio-demographic factors included in this analysis were age; gender; income poverty; 
education; survey year and race. Income poverty is calculated in the NHANES datasets as the 
ratio of each participant’s household income to the poverty threshold. The poverty threshold 
in turn is determined from the US Department of Health and Human Services poverty 
guidelines that are used to decide eligibility to a suite of federal welfare programmes.      
2.0: DATA ON HEALTH RISK BEHAVIOURS 
Excess alcohol use, cigarette smoking; physical inactivity; unhealthy diet; and illicit drug use 
are regarded as the major HRBs detrimental to health. We characterised each survey 
participant in terms of these behaviours.  A distinction was drawn throughout between 
current HRBs (i.e. a HRB present at the time of survey interview) and past HRBs (i.e. 
present in the past but not at the time of survey interview). Current excess alcohol use was 
defined as drinking, on average, >2 drinks/day in the 12 months preceding the survey 
interview. We examined three severity levels of current excess use. These were mean 
consumption of: i) >2 but <4 drinks/day; ii) ≥4 but <5 drinks/day; and iii) ≥5 drinks/day, in 
the 12 months preceding survey examination. Participants who reported consuming “at any 
time in their life, five alcoholic drinks or more almost every day” were considered to be 
former heavy alcohol users providing their current alcohol intake was below the 5 drinks/day 
threshold. For all the above measures of alcohol use, one drink was defined as that containing 
14g of pure alcohol (equivalent to 1.75 UK units). Current drug use was defined as the use of 
an illicit drug at least once within the past year. We considered two types of current drug 
users; those who had used a needle in the last year to inject drugs and those who had not.  
Individuals who had not used drugs in the last year but had done so in the past were 
considered to be former drug users. Similarly, we distinguished between former drug users 
that had ever injected drugs with a needle from former drug users who had not. Changes to 
the drug-use questionnaire in 2005 meant that we could not keep the definition of non-
injecting drug exactly the same for all survey participants. For 1999-2004 participants 
therefore, non-injecting drug use refers to use of “cocaine or any other street drug (excluding 
marijuana)”, whereas for 2005-2010 participants, it refers more specifically to use of 
“cocaine, crack cocaine, heroin or methamphetamine”. Unhealthy eating was based on the 
amount of fruit and vegetables the participant reported consuming in the 24-hour period prior 
to survey examination. We used the US Department of Agriculture food codes to distinguish 
 fruits/vegetables from other foods (see eTable 1). We defined a single portion of fruit or 
vegetable as that which weighs 30g or 80g in dried or non-dried forms, respectively.  We 
defined “healthy eating” as consumption of at least 3 distinct portions of fruit/vegetable 
(analogous to definitions adopted in previous studies[25]). By the same token, participants 
who consumed less than three portions of fruit/vegetables (or consumed >=3 portions, but 
with those portions spread out across less than three distinct fruits or vegetables) were 
considered in this analysis to have an “unhealthy” diet. Data on past/former unhealthy eating 
habits are not available in NHANES. Current physical inactivity was defined as the absence 
of regular moderate or vigorous physical activity at the time of the survey interview. As with 
illicit drug use, modifications to the physical activity questionnaire meant that inactivity was 
defined slightly differently according to survey year. For 1999-2004 participants, inactivity 
was defined as the absence of any moderate/vigorous activity in the 30 days prior to survey 
interview, whereas for 2005-2010 participants, inactivity was defined as reporting the 
absence of any moderate/vigorous activity “in a typical week”.  No data on former physical 
inactivity was available in NHANES. In relation to cigarette smoking, a participant was 
considered to be a current smoker, if at the time of their interview they reported smoking 
cigarettes “now” (either “every day” or on “some days”). Individuals who were not current 
smokers, but who reported smoking more than 100 cigarettes at any point in their life were 
categorised as former smokers.  
Of note, information on cigarette smoking, alcohol consumption, physical activity and dietary 
intake were elicited from participants via face-to-face interviews, conducted either at the 
participant’s home or at the NHANES MEC. Data on illicit drug use was collected with 
greater anonymity through a computer-assisted self-administered questionnaire carried out at 
the MEC. 
3.0: DATA ON CHRONIC HEPATITIS C INFECTION STATUS 
NHANES participants submit a blood sample that is later tested for viral markers, including 
markers of CHC, hepatitis B and human immunodeficiency virus (HIV) infection. We 
defined CHC infection as positivity for both HCV antibodies and HCV RNA. Individuals 
testing negative for HCV antibodies were considered to be without CHC. Individuals testing 
positive for HCV antibodies but negative for HCV RNA were also considered to be without 
CHC. Individuals with unknown CHC status (as indicated by a missing or indeterminate 
 result for HCV antibodies, or a missing result for HCV RNA if the participant tested positive 
for HCV antibodies) were excluded from this analysis.   
4.0: DATA ON COMORBID MEDICAL CONDITIONS 
We included data on whether the following conditions had ever been diagnosed by a doctor 
or other health professional: heart disease, chronic obstructive pulmonary disease; cancer and 
diabetes. Heart disease was defined as previous diagnosis of congestive heart failure, 
coronary heart disease, angina, or a prior heart attack. Chronic obstructive pulmonary disease 
was defined as emphysema or chronic bronchitis. Obesity was defined as having a body mass 
index of ≥30 kg/m2. Current infection with other blood borne viruses was based on positivity 
for hepatitis B surface antigen protein and /or antibodies to HIV. Of note, testing for HIV 
antibodies were only carried out for participants aged 0-49 yrs at baseline, and so data are 
missing for a large portion of our complete sample. 
 
5.0: DATA ON SUBSEQUENT MORTALITY STATUS 
The vital status at 31 Dec 2011 of survey participants was ascertained through linkage to the 
2015 public-use linked mortality file. This file is generated through probabilistic matching of 
NHANES participants to the US National Death Index. [26] 
 
STATISTICAL ANALYSIS 
Our analysis comprised two strands: Firstly assessment of the prevalence difference in HRBs 
according to CHC infection, and secondly assessment of the contribution that these 
prevalence differences make to the excess mortality risk. Both analyses were carried out 
initially on the whole cohort, and then specifically for participants aged 45-70 years at 
baseline. This latter subgroup analysis was intended to mirror the eligibility criteria for one-
time HCV antibody testing, currently recommended for individuals in the US born between 
1945 and 1965. [27] All analyses took account of the multistage complex sampling design of 
NHANES.[23] Each participant was assigned the sample weight provided on the dietary 
questionnaire files (as this was our smallest analysis subpopulation). When combining 
participants from different survey cycles (i.e. years 1999-2010), we re-calibrated these 
weights so that our final pooled sample mirrored the socio-demographic composition of the 
 US civilian non-institutionalised population at the time of year 2000 census (see [28] for 
further details). Variance estimates were adjusted via Taylor series linearization throughout.  
ANALYSIS 1:  PREVALENCE OF HRBS ACCORDING TO CHC INFECTION STATUS 
We calculated the prevalence of current and former HRBs in participants according to CHC 
infection status. Each prevalence estimate was standardised for baseline age, race, education 
and gender, using a standard population derived from the age/race/education/gender 
distribution of survey participants with CHC infection (see eTable 1). In this way, for 
participants with CHC infection, our estimates reflect the actual observed prevalence of each 
HRB, whereas for participants without CHC, our estimates reflect the expected prevalence 
given the same socio-demographic distribution as per the CHC infected population. 
Individuals missing data for a given HRB were not included in the prevalence estimate for 
that HRB, but were included in the prevalence estimate for other HRBs where the requisite 
data was not missing - as a result, each HRB prevalence estimate can be based on a slightly 
different denominator.   
ANALYSIS 2: CONTRIBUTION OF HRBS TO EXCESS MORTALITY IN PERSONS 
WITH CHC  
A Poisson regression model was fitted to determine the mortality rate ratio (MRR) for CHC 
infection versus no CHC infection after adjustment for socio-demographic factors. This initial 
model is referred to as the base model. We then determined the % attenuation (i.e. the % 
reduction) in the base model MRR following further adjustment for: comorbid medical 
conditions; former HRBs; current HRBs; and former+current HRBs. Participants missing 
data for one or more covariates were included in regression models via the generation of 
missing indicator variables. Thus, this ensured that the base model and all further adjustment 






 RESULTS:  
DESCRIPTION OF FINAL SAMPLE: 
29,130 participants met our inclusion criteria, 1631 (5.6%) were then excluded on account of 
missing CHC infection status, and a further 31 (0.1%) participants were discounted because 
their mortality status at Dec 2011 could not be ascertained. The final sample therefore was 
27,468 individuals, of which 363 (weighted prevalence: 1.2%) had CHC infection at baseline. 
The complete breakdown of the cohort in terms of socio-demographic factors, comorbid 
medical conditions and HRBs is shown in eTable 2. Relative to those without CHC, 
participants with CHC were more likely to: be older; be male; be non-hispanic black, be 
living below the poverty threshold, and to not have more than a high school education, (see 
Table.1). At the end of follow-up, 6.2 years on average after the baseline survey interview, 
2599 (9.5%) participants in our sample had died (43 of these deaths were among persons with 
CHC infection – see eTable.3). Crude mortality rates by CHC status are shown in eTable 4. 
In our final sample, the proportion of participants missing data for a given covariate was low 
at 0-6% (see eTable 2). The two exceptions to this were data on illicit drug use (which was 
missing for 25.5% of participants) and data on HIV infection status (missing for 38.8% of 
participants).  
ANALYSIS 1 – PREVALENCE OF HRBS ACCORDING TO CHC INFECTION STATUS 
HRBs were more prevalent among individuals with CHC infection versus individuals 
without. This applied particularly to current HRBs. Current excess alcohol use was 2.3 times 
more prevalent (18.7% for CHC-infected versus 8.3% for CHC uninfected; p<0.001). Current 
cigarette smoking was 2.3 times as prevalent (63.8% for CHC-infected versus 28.2%, 
p<0.001); Current injecting drug use was ninety-three times as prevalent (9.3% for CHC-
infected versus 0.1% for CHC uninfected, p=0.001). Current non-injecting drug use was 3.4 
times as prevalent (16.2% for CHC-infected versus 4.7% for CHC uninfected, p<0.001). 
Comparable differences were observed in our subgroup analysis of patients aged 45-70 years 
at baseline (see Table 2). The prevalence difference (i.e. the absolute difference in prevalence 
between participants with CHC versus participants without) is shown for each HRB in 
descending order in Figure.1  
 
 ANALYSIS 2; CONTRIBUTION OF HRBS TO EXCESS MORTALITY IN PERSONS 
WITH CHC  
In our final sample of 27,468 survey participants, the MRR comparing individuals with CHC 
infection to individuals without, after adjustment for socio-demographic factors alone, was 
2.36 (95% CI: 1.60-3.49). After adjusting for socio-demographic factors + comorbid medical 
conditions (see model #17), the MRR attenuated only marginally, by 0.7%, to 2.35 (95% CI: 
1.62-3.41). Similarly, when adjusting for socio-demographic factors + former HRBs (see 
model#18), the MRR attenuated minimally to 2.27 (95% CI: 1.47-3.52). Conversely, when 
adjusting for socio-demographic factors + current HRBs (model #19), the MRR attenuated by 
51.5% to 1.66 (95% CI: 1.19-2.32). The single HRB associated with greatest attenuation was 
current cigarette smoking (30% attenuation following adjustment for this behaviour alone). 
Total HRB adjustment (i.e. adjustment for former and current HRBs) attenuated the MRR by 
50.7% to 1.67 (95% CI: 1.14-2.44).  
In our subgroup analysis of individuals aged 45-70 years at baseline (N=10,810), the socio-
demographic-adjusted MRR was smaller than for the full cohort at 1.68 (95% CI: 0.89-3.20). 
Attenuation due to HRB adjustment was even more pronounced in this subgroup versus the 
full cohort. For instance, adjustment for current HRBs attenuated the MRR by 69.6%, whilst 











 DISCUSSION:  
MAIN FINDINGS: 
The existence of a substantial excess mortality risk for individuals with CHC infection in 
resource-rich countries [2-7] is a major clinical and public health concern. Although the 
detrimental effect of CHC itself is the most obvious explanation for this phenomenon, other 
factors may be contributing too. In this study, we used unique data from a large US 
community survey to examine the extent to which HRBs contribute to excess mortality in this 
population. As expected, we observed a considerable excess mortality risk for individuals 
with CHC infection after adjusting for socio-demographic factors. Specifically, the all-cause 
mortality rate for individuals with CHC was 2.4 times higher than for individuals without 
CHC (an excess which, if extrapolated to the US population as a whole, equates to ~39,000 
surplus CHC deaths every year - see Appendix A). However, the key finding from this study 
is that this excess mortality risk attenuated considerably - by 50.7% - following subsequent 
adjustment for all HRBs. This suggests that although CHC is a well-known cause of hepatic 
and extrahepatic disease, half the mortality excess may actually reflect the consequences of 
HRBs rather than CHC itself. The impact of ameliorating HRBs in the CHC-infected 
population could therefore be considerable, and so it is striking that the evidence-base on this 
topic is so thin. In a recent systematic review, Doyle et al could identify only two RCTs for 
an alcohol reduction intervention in patients with HCV. [29] In like vein, we were unable to 
identify a single RCT evaluating a smoking cessation intervention for patients with HCV in 
our own brief literature search (see appendix B). Overall this study cautions that - 
advancements in antiviral therapy [30] aside- a sizeable excess mortality risk is likely to 
persist for individuals with past/present CHC unless more attention is paid to tackling 
coexisting HRBs.  
 
US BIRTH COHORT SCREENING:  
In 2012, the Centre for Disease Control (CDC) recommended that all US individuals born 
between 1945 and 1965 receive one-time testing for HCV.[27]. When we restricted our 
analysis to individuals aged 45-70 years (i.e. to roughly mirror the age range that birth cohort 
screening will in practice be applied to) we observed even higher levels of attenuation to that 
of the full cohort (69.1%), and similarly saw that most of the attenuation was driven by 
adjustment for current HRBs (particularly cigarette smoking). Although this result does not 
undermine birth cohort screening as such (i.e. whilst the MRR for this subgroup was not 
 statistically significant, this probably reflects a lack of statistical power as opposed to a real 
non-effect of CHC on mortality), they do persuade that addressing HRBs should form a 
strong component of this intervention. At present, this is arguably not the case. Although the 
CDC do recommend that those testing positive for HCV be advised to decrease their alcohol 
consumption, they concede that the evidence-base on how to actually deliver this advice is 
limited. [27] Further US birth cohort screening omit guidance on counselling for other 
relevant HRBs (notably for cigarette smoking, which led to the strongest attenuation in the 
excess mortality risk for this population).   
LIMITATIONS OF STUDY 
There are several limitations of this study. We had no data on individuals with CHC infection 
clearing infection via antiviral therapy during follow-up. In theory this could bias the size of 
the excess mortality risk towards the null. However, the rate of clearing CHC through 
antiviral treatment was minimal in the US during the time period of this analysis – only about 
1.4 SVRs per year for every 100 infected persons (see Appendix C) – and so is unlikely to 
affect our conclusions.  A second limitation relates to selection bias; survey participants who 
completed both the mobile examination and dietary components of this survey (i.e. the 
inclusion criteria of this study) may differ from those who did not. However, the survey 
weights assigned to survey participants are calibrated to adjust for differential response by 
socio-demographic factors,[31] and in any case non-response rates were reasonably low (i.e. 
67% of those invited to participate in NHANES fulfilled the inclusion criteria of this study –
see eFig.1). Thirdly, NHANES is a survey of the civilian non-institutionalised population and 
therefore excludes individuals who are homeless or in prison (two subpopulation where the 
prevalence of HCV is high[32-33]). Thus, whilst NHANES may not perfectly represent the 
general CHC infected population in the US, it will provide a far more representative sample 
than the alternative of diagnosis/treatment cohorts. Fourthly, some individuals in our cohort 
were missing data for one or more HRBs. Mostly the proportion with missing data was low 
(<5%), but it was more common in relation to data on illicit drug use (where 25.5% of our 
final sample were missing data on this HRB). The high frequency of missing drug use data 
was due to the NHANES survey protocol rather than individuals choosing to not respond to 
the requisite questions. For the 1999-2006 and 2007-2008 survey years, questions relating to 
illicit drug use were not posed to participants aged ≥60 years and ≥70 years, respectively. It is 
possible that the age/survey year patterning of this missing data could have caused bias with 
respect to the association between illicit drug use and mortality risk. Fifthly, this study would 
 ideally have stratified % attenuation across a number of socio-demographically defined 
subgroups. However, low statistical power (stemming from only 43 deaths in the CHC 
infected population overall) precluded us from doing this in a robust way. For a similar 
reason, we were not able to stratify % attenuation by cause of death. That said, we did 
examine the categories of death contributing most to the excess mortality in CHC participants 
(see Appendix D), and found that 30% of the excess was due to deaths from accidents 
(which, prima facie, is consistent with a strong HRB contribution). However, this 
supplementary analysis is again limited by the small number of deaths, and the broad cause-
of-death categories themselves (the selection of which, we had no control over). A final 
limitation is that the HRB data were measured at a single cross-sectional time point. 
Longitudinal data would have been superior in that it would have allowed us to take account 
of any changes in HRBs occurring over the course of follow-up. Previous work has suggested 
that analysing HRBs on the basis of cross-sectional data, as opposed to longitudinal data, will 
understate contribution of HRBs on mortality – particularly with regard to the contribution of 
poor diet and physical inactivity [34].  
CONSISTENCY WITH PREVIOUS NHANES RESEARCH 
Our analysis is consistent with previous studies of NHANES data, establishing: a) a 
heightened prevalence of current alcohol use among persons with hepatitis C [35]; and b) that 
alcohol use is an independent predictor of mortality among persons with hepatitis C [36]. 
More notably however, these findings are consistent with a study by El-Kamary et al [37] 
which also indicated substantial attenuation in the mortality excess following adjustment for a 
broad range of co-factors. However, there were some important limitations of this study. 
Firstly, it was based on historical NHANES III data (the interviews for which were carried 
20-25 years ago between 1988 and 1994); as such the data may not be representative of 
individuals living with CHC infection today. Secondly, their analysis did not include detailed 
data on HRBs such as dietary, exercise, past alcohol use, and injecting drug use history. The 
absence of these data precludes a comprehensive assessment of the total impact of HRBs. 
Thirdly, El-Kamary et al asked a fundamentally different question of the data to that of this 
study – namely, does HCV remain independently associated with higher mortality even after 
adjusting for all relevant confounders? As such, they did not report attenuation following 
adjustment for HRBs as we have done here.  
SUMMARY 
 In conclusion, individuals with CHC infection in the US exhibit a considerable excess 
mortality risk. Yet, about half of this excess may reflect high levels of HRBs as opposed to 
the effects of CHC infection itself. This study therefore highlights the importance of a public-
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